Results 61 to 70 of about 61,613 (221)

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. [PDF]

open access: yesPLoS ONE, 2013
The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways.
Erica L Bradshaw-Pierce   +8 more
doaj   +1 more source

Lactate‐H3K18la‐RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair

open access: yesAdvanced Science, EarlyView.
A lactate‐H3K18la epigenetic axis upregulates RPL11 to drive gemcitabine resistance in pancreatic cancer. RPL11 orchestrates chemoresistance through a dual, compartmentalized role: enhancing cytoplasmic protein synthesis via EEF1A1 stabilization and promoting nuclear DNA damage repair by co‐activating PARP14, thus ensuring robust cell survival ...
Lijun Zhao   +10 more
wiley   +1 more source

อิริโนทีแคน ในมุมมองเภสัชพันธุศาสตร์ Irinotecan: Pharmacogenetic Perspective [PDF]

open access: yes, 2021
อิริโนทีแคนเป็นยาเคมีบำบัดที่ใช้ในการรักษามะเร็งหลายชนิด ได้แก่ มะเร็งลำไส้ใหญ่และทวารหนัก มะเร็งปอด มะเร็งตับอ่อน ยามีลักษณะเป็น prodrug ที่ต้องผ่านกระบวนการไฮโดรไลซิสล์ (hydrolysis) เป็น 7-ethyl-10-hydroxy-camptothecin (SN-38) ซึ่งเป็นสารที่มีฤทธ ...
Wonganan, Piyanuch   +1 more
core  

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Ryosuke Fukushima   +9 more
wiley   +1 more source

The Protective Effect of Ethanolic Extract of Mentha spicata Against Irinotecan-Induced Mucositis in mice

open access: yesIraqi Journal of Pharmaceutical Sciences, 2019
Irinotecan induced-mucositis is an inflammatory event of intestine caused by an increase in concentration of active metabolite 7­ethyl­10-hydroxycamptothecin (SN­38) in the intestine. Irinotecan must first be converted by a carboxylesterase (CES) to the
Aliaa Abdul sattar Abdul jabbar   +1 more
doaj   +1 more source

Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China

open access: yesBMJ Open, 2023
Objectives The hepatotoxicity of irinotecan has been widely implicated in the treatment of multiple solid tumours. However, there are few studies on the influencing factors of irinotecan-induced hepatotoxicity.
Yi Xu   +9 more
doaj   +1 more source

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

open access: yesBMC Cancer
Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC.
Feride Yılmaz   +9 more
doaj   +1 more source

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

open access: yesBMC Cancer, 2022
Background AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks.
S. Lindsey Davis   +14 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

open access: yesESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy